Page 34 - Drug Controller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ahead of the dry-run for COVID-19 vaccine in the national capital, Union Health Minister Harsh Vardhan on Friday held a review meeting with the Delhi government officials for the preparations of the mock drill, which is scheduled for January 2. The minister was speaking to the Delhi government officials via video-conference. He said the procedure of the vaccination drive is similar to the election preparations. "The procedure of the vaccination drive is the same as the election. In any election, we train people at the booth the same way. We need more manpower so we have to train the people...

Union Minister Harsh Vardhan (File Photo) Medical teams should be trained for COVID-19 vaccination on lines of preparations made during elections: Harsh Vardhan ANI | Updated: Jan 01, 2021 19:05 IST By Ashoke Raj New Delhi [India], January 1 (ANI): Union Health Minister Harsh Vardhan on Friday chaired a high-level meeting to review preparedness at session sites across the country for COVID-19 vaccination trial run on Saturday and said just like preparations during elections, each member of medical teams should be trained responsibly. The minister urged ...

Aditi Tandon New Delhi, December 30 The UK regulator on Wednesday approved the Oxford University Astra Zeneca COVID-19 vaccine for emergency use in its population a day after the country reported a whopping 40,000 new cases as it reeled under the impact of a new more infectious mutant strain. India has yet to give its approval to the vaccine.  The Drug Controller of India, which held a meeting on a pending application from Serum Institute of India for emergency use approval of the vaccine, asked for more data from the SII as well as Bharat Biotech. Serum Institute is the production collabora...

Last Updated: BBL's Covaxin's Phase-1 Trial's Interim Findings Indicate Vaccine 'well-tolerated' Interim findings from phase-1 trials of BBL's 'Covaxin' was well-tolerated in all dose groups with no serious adverse events, as it awaits DGCI's emergency nod As both Serum Institute of India (SII) and Bharat Biotech Ltd (BBL) await the Drug Controller of India (DGCI)'s approval of emergency use of their Coronavirus (COVID-19) vaccines, interim findings from phase-1 trials of BBL's 'Covaxin' was well-tolerated in all dose groups with no serious adverse events. Moreover, after the first vacci...